InnoCare Pharma Limited (HKG:9969) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Feb 18
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Biotech Industry Analysis
UpdatedFeb 21, 2025
DataAggregated Company Financials
Companies49
- 7D11.7%
- 3M5.8%
- 1Y18.9%
- YTD11.3%
The Biotech industry has gained 12% in the last week and Akeso up 15%. Meanwhile, Cutia Therapeutics actually underperformed within the industry, shrinking 12% in the last week. In the last 12 months, the industry was up 19%. As for the next few years, earnings are expected to grow by 39% per annum.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 21 Feb 2025 | HK$405.7b | HK$52.1b | -HK$17,347,833,321.60 | 14.2x | -23.4x | 7.8x |
| Sun, 19 Jan 2025 | HK$348.5b | HK$51.8b | -HK$17,198,216,943.69 | 12.8x | -20.3x | 6.7x |
| Tue, 17 Dec 2024 | HK$389.3b | HK$52.0b | -HK$17,273,815,951.71 | 11x | -22.5x | 7.5x |
| Thu, 14 Nov 2024 | HK$395.7b | HK$52.4b | -HK$17,465,717,532.43 | 11.4x | -22.7x | 7.5x |
| Sat, 12 Oct 2024 | HK$408.5b | HK$52.6b | -HK$18,016,226,960.01 | 12.2x | -22.7x | 7.8x |
| Mon, 09 Sep 2024 | HK$336.6b | HK$52.4b | -HK$19,014,139,979.15 | 11.2x | -17.7x | 6.4x |
| Wed, 07 Aug 2024 | HK$328.8b | HK$50.3b | -HK$19,745,832,215.85 | 11.5x | -16.7x | 6.5x |
| Fri, 05 Jul 2024 | HK$316.6b | HK$49.6b | -HK$19,434,376,607.24 | 11.7x | -16.3x | 6.4x |
| Sun, 02 Jun 2024 | HK$340.5b | HK$49.8b | -HK$19,538,408,792.63 | 12x | -17.4x | 6.8x |
| Tue, 30 Apr 2024 | HK$360.3b | HK$49.7b | -HK$19,502,930,130.42 | 12.1x | -18.5x | 7.3x |
| Thu, 28 Mar 2024 | HK$342.7b | HK$49.5b | -HK$19,178,748,110.55 | 13.7x | -17.9x | 6.9x |
| Sat, 24 Feb 2024 | HK$340.8b | HK$46.8b | -HK$20,173,383,442.48 | 17x | -16.9x | 7.3x |
| Mon, 22 Jan 2024 | HK$339.3b | HK$47.0b | -HK$20,275,134,851.00 | 16.3x | -16.7x | 7.2x |
| Wed, 20 Dec 2023 | HK$395.7b | HK$47.0b | -HK$20,266,729,302.00 | 17.4x | -19.5x | 8.4x |
| Fri, 17 Nov 2023 | HK$410.1b | HK$45.2b | -HK$18,711,404,914.00 | 17.9x | -21.9x | 9.1x |
| Sun, 15 Oct 2023 | HK$400.9b | HK$44.9b | -HK$19,108,661,851.00 | 14.7x | -21x | 8.9x |
| Tue, 12 Sep 2023 | HK$413.7b | HK$45.0b | -HK$18,950,523,216.00 | 15.8x | -21.8x | 9.2x |
| Thu, 10 Aug 2023 | HK$389.0b | HK$35.4b | -HK$23,304,596,400.00 | 22.4x | -16.7x | 11x |
| Sat, 08 Jul 2023 | HK$397.5b | HK$35.4b | -HK$23,261,472,051.00 | 24.6x | -17.1x | 11.2x |
| Mon, 05 Jun 2023 | HK$415.9b | HK$36.0b | -HK$23,718,069,081.00 | 26.9x | -17.5x | 11.6x |
| Wed, 03 May 2023 | HK$445.0b | HK$36.7b | -HK$23,526,742,121.00 | 18.1x | -18.9x | 12.1x |
| Fri, 31 Mar 2023 | HK$419.6b | HK$35.3b | -HK$25,716,402,512.00 | 12.2x | -16.3x | 11.9x |
| Sun, 26 Feb 2023 | HK$403.3b | HK$34.3b | -HK$34,519,333,916.00 | 31.2x | -11.7x | 11.8x |
| Tue, 24 Jan 2023 | HK$452.0b | HK$34.9b | -HK$35,245,225,961.00 | 29.8x | -12.8x | 13x |
| Thu, 22 Dec 2022 | HK$371.8b | HK$33.6b | -HK$33,898,900,822.00 | 23x | -11x | 11.1x |
| Sat, 19 Nov 2022 | HK$379.5b | HK$33.0b | -HK$33,255,843,629.00 | 16.8x | -11.4x | 11.5x |
| Mon, 17 Oct 2022 | HK$297.6b | HK$33.7b | -HK$32,213,028,064.00 | 15.5x | -9.2x | 8.8x |
| Wed, 14 Sep 2022 | HK$356.2b | HK$34.5b | -HK$33,767,111,427.00 | 16.9x | -10.5x | 10.3x |
| Fri, 12 Aug 2022 | HK$339.9b | HK$32.9b | -HK$46,378,297,257.00 | 12.1x | -7.3x | 10.3x |
| Sun, 10 Jul 2022 | HK$375.7b | HK$33.1b | -HK$46,688,664,217.00 | 14.4x | -8x | 11.4x |
| Tue, 07 Jun 2022 | HK$333.3b | HK$34.3b | -HK$46,192,775,584.00 | 13.5x | -7.2x | 9.7x |
| Thu, 05 May 2022 | HK$321.2b | HK$34.4b | -HK$45,764,117,876.00 | 13.5x | -7x | 9.3x |
| Sat, 02 Apr 2022 | HK$349.7b | HK$36.5b | -HK$46,136,389,470.00 | 16.5x | -7.6x | 9.6x |
| Mon, 28 Feb 2022 | HK$339.1b | HK$33.9b | -HK$31,130,917,530.00 | 13x | -10.9x | 10x |
Price to Earnings Ratio
-10.9x
Current Industry PE
- Investors are pessimistic on the Hong Kong Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 9.2x is higher than the industry's current PS ratio of 7.8x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 15% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 3.24% | |
| Healthcare | 10.49% | |
| Biotech | 11.72% | |
| Biotech | 11.72% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 9926 Akeso | HK$68.95 | 14.5% +HK$7.9b | 51.4% | PS30.8x | |
| 6990 Sichuan Kelun-Biotech Biopharmaceutical | HK$213.40 | 16.9% +HK$7.0b | 100.4% | PS24.1x | |
| 1801 Innovent Biologics | HK$41.70 | 11.2% +HK$6.9b | 4.8% | PS8.6x | |
| 1952 Everest Medicines | HK$45.10 | 20.9% +HK$2.5b | 123.3% | PS32.4x | |
| 2410 TYK Medicines | HK$31.00 | 26.8% +HK$2.4b | n/a | PE-25.1x |
